Evidence map›Paper›PMID 38629593›Full record

ArticleFuture oncology (London, England)2024

Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study.

Muhammad Furqan, Siddharth Karanth, Ravi K Goyal, Beilei Cai, Julien Rombi, Keith L Davis, Nydia Caro, Teddy Saliba

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Muhammad FurqanUniversity of Iowa Hospitals & Clinics, Carver College of Medicine, Iowa City, IA 52242, USA.ORCID 0000-0003-3137-2053
Siddharth KaranthRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0002-4923-2692
Ravi K GoyalRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0003-1632-036X
Beilei CaiNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.ORCID 0000-0002-2762-3908
Julien RombiRTI Health Solutions, Research Triangle Park, NC 27709, USA.
Keith L DavisRTI Health Solutions, Research Triangle Park, NC 27709, USA.ORCID 0000-0002-0044-7107
Nydia CaroNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
Teddy SalibaNovartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.
RTI Health Solutions · USNovartis (United States) · USUniversity of Iowa Hospitals and Clinics · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Novartis Pharmaceuticals Corporation
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationProto-Oncogene Proteins c-metAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzamidesFemaleHumansImidazolesImmunotherapyMaleMiddle AgedRetrospective StudiesBenzamidescapmatinibImidazolesMET protein, humanProto-Oncogene Proteins c-metTriazinescapmatinibmedical chart reviewnon-small-cell lung cancerreal world evidencetreatment effectiveness

Identifiers

PMID38629593
PMCPMC11457592
OpenAlexW4394872876

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.